Mavacamten
- Generic Name
- Mavacamten
- Brand Names
- Camzyos
- Drug Type
- Small Molecule
- Chemical Formula
- C15H19N3O2
- CAS Number
- 1642288-47-8
- Unique Ingredient Identifier
- QX45B99R3J
- Background
Mavacamten is a myosin inhibitor indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM). It received initial US FDA approval in 2022, and it is one of the first myosin inhibitors to be used in humans. Mavacamten was also approved by Health Canada in October 2022 and by EMA in July 2023 for the same indication.
- Indication
Mavacamten is indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms by the FDA, Health Canada, and the EMA.
- Associated Conditions
- Symptomatic Obstructive Hypertrophic Cardiomyopathy
Efficacy of Mavacamten in Patients With Symptomatic Latent Obstructive Hypertrophic Cardiomyopathy
- Conditions
- HCM - Hypertrophic CardiomyopathyMavacamten
- Interventions
- First Posted Date
- 2025-04-27
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Xu Liu
- Target Recruit Count
- 78
- Registration Number
- NCT06947590
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, China
Efficacy of Mavacamten Combined With Radiofrequency Ablation in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
- Conditions
- Obstructive Hypertrophic CardiomyopathyMavacamtenRadiofrequency Ablation
- Interventions
- Procedure: radiofrequency ablation
- First Posted Date
- 2025-03-04
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT06856265
Real-world Patient Reported Outcomes Among Patients Treated With Camzyos
- First Posted Date
- 2024-08-13
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 118
- Registration Number
- NCT06551129
- Locations
- 🇺🇸
Analysis Group Inc., Boston, Massachusetts, United States
A Retrospective Cohort Study of Mavacamten Patient Support Program in Canada
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 685
- Registration Number
- NCT06549608
- Locations
- 🇨🇦
St. Paul's Hospital, Vancouver, British Columbia, Canada
COLLIGO-HCM: A Multinational Observational Study of the Real-World Effectiveness of Mavacamten Among Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
- Conditions
- Hypertrophic Cardiomyopathy (HCM)
- Interventions
- Drug: Approved Hypertrophic Cardiomyopathy drug treatments
- First Posted Date
- 2024-04-18
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 500
- Registration Number
- NCT06372457
- Locations
- 🇺🇸
IQVIA, Durham, North Carolina, United States
Real-World Effectiveness of Mavacamten in Canada
- Conditions
- Obstructive Hypertrophic Cardiomyopathy (oHCM)
- Interventions
- First Posted Date
- 2024-03-29
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 100
- Registration Number
- NCT06338202
- Locations
- 🇨🇦
London Health Science Centre (LHSC), London, Ontario, Canada
A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 40
- Registration Number
- NCT06253221
- Locations
- 🇺🇸
Rady Children's Hospital-San Diego, San Diego, California, United States
🇺🇸Children's Hospital of Philadelphia-Center for Childhood Cancer Research, Philadelphia, Pennsylvania, United States
🇨🇦The Hospital for Sick Children (SickKids), Toronto, Ontario, Canada
A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
- First Posted Date
- 2023-11-27
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 600
- Registration Number
- NCT06146660
- Locations
- 🇰🇷
Local Institution - 0001, Seoul, Korea, Republic of
🇰🇷Novotech Laboratory Korea Co., Ltd., Seoul, Korea, Republic of
A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy
- First Posted Date
- 2023-11-01
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 85
- Registration Number
- NCT06112743
- Locations
- 🇮🇹
Local Institution - 0056, Pavia, Lombardia, Italy
🇺🇸Cedars Sinai Medical Center - 1207 San Vicente Blvd, Los Angeles, California, United States
🇺🇸Piedmont Hospital, Atlanta, Georgia, United States
Effect of Mavacamten Treatment on Coronary Flow Reserve in oHCM
- First Posted Date
- 2023-09-05
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Michael Ayers
- Target Recruit Count
- 20
- Registration Number
- NCT06023186
- Locations
- 🇺🇸
University of Virginia, Charlottesville, Virginia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.